Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
about
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patientsHarnessing the immune system to improve cancer therapyCheckpoint Inhibitors and Their Application in Breast CancerAdoptive immunotherapy against ovarian cancerImmunotherapy for cancer in the central nervous system: Current and future directionsCancer immunotherapy: the beginning of the end of cancer?Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Updates in Therapy for Advanced MelanomaChimeric Antigen Receptors Modified T-Cells for Cancer TherapyIdentifying Individual T Cell Receptors of Optimal Avidity for Tumor AntigensTargeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor ImmunityT-Cell Therapy: Options for Infectious DiseasesImmunotherapy of Childhood SarcomasStrategies for combining immunotherapy with radiation for anticancer therapyMelanoma: From Incurable Beast to a Curable Bet. The Success of ImmunotherapyReflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune ResponseThe Evolution of T-cell Therapies for Solid MalignanciesAdoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergyAcquired and intrinsic resistance in cancer immunotherapyT lymphocytes targeting native receptorsImmune reconstitution in chronic lymphocytic leukemiaPathways and therapeutic targets in melanomaPrimer on tumor immunology and cancer immunotherapySorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookNovel immunotherapies for hematologic malignanciesAdoptive T-cell therapy for LeukemiaToxicities of Immunotherapy for the PractitionerPotential for immunotherapy in soft tissue sarcomaAdoptive cell therapy for sarcomaγδ T cells for cancer immunotherapy: A systematic review of clinical trialsThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentBone specific immunity and its impact on metastasisCD4 T-cell immunotherapy for chronic viral infections and cancerCurrent translational and clinical practices in hematopoietic cell and gene therapyChimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challengesTargeting the tumor vasculature to enhance T cell activityGenetically modified T cells in cancer therapy: opportunities and challengesLineage relationship of effector and memory T cellsProliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques
P2860
Q24598792-DAAFB73D-23EA-4103-B7F7-81D915A7ED35Q26738698-F65209C0-9D92-4CF1-9543-16E24B13AA5CQ26745442-BBDEDA03-9B43-490A-B872-4D86F3B896A7Q26748905-26EBDB1F-F311-4345-8BF5-B07817E8875AQ26750765-AEA40DD3-0313-40A9-9977-FDE0BA9658A4Q26752277-3941F815-8CD9-4FB5-9E39-BA92E45E2F91Q26765429-AA43909C-8D49-4C89-B8E7-39A70F68B348Q26771119-6EF8693C-08D4-416A-91B0-3C27CC5FEDCCQ26773309-367F82F2-A9B5-47A0-9FF8-9A8B94E6E2EBQ26774669-632F114E-1240-4E7C-98F3-ED71D9115852Q26782201-34A91784-8F25-49B3-8D25-EC9F24DE024BQ26786661-B59AEF6E-C180-4A53-BE22-2B77258AC683Q26795369-CE718D13-BA57-4CE0-A6DB-018E3F5E892BQ26796675-DDA1838D-9719-4400-9E50-07155069B550Q26798404-FB208A94-FB45-4C9E-BEC6-C8E8C2407F47Q26799073-D3C839BE-2905-49D5-BCB9-2CF38A90929EQ26799372-4FF39CDE-ABC7-433E-BD35-6BF8C3749DA1Q26822793-1E2A5B40-57A3-485F-952C-FFA0A1E479E9Q26827701-8AFAD0F2-6891-41A8-8382-11D1A3CE50F0Q26853345-80908F95-12D8-4A6D-826E-D88967A0B1A6Q26865561-0E93AF20-EE60-438E-B546-9B06983A5FDBQ26865736-535D326D-892D-43E2-8350-73BBC6919CFCQ27001126-A54DBE40-96F9-4F15-92BD-9D770F0FF5D8Q27002575-741C1D1C-A01B-43EF-906A-B129F726AEBFQ27004178-4993F86E-4376-4C9D-A62B-AF48416FD140Q27004436-D832192F-E382-427C-B60A-B486EF9FD462Q27006934-A408A461-3C3B-4813-AA18-2DC42D8E45B2Q27008140-2ED3C385-C28E-45ED-B1F4-DC2CFF86BF52Q27008830-A1214919-0C05-47CF-8BC6-2DC5C4238AF4Q27009541-FE6F93EB-2E3D-473D-85D9-1320C6C982CCQ27021705-27397CC8-9196-43C0-A300-B5CDCEF247BFQ27022789-4F2D9048-E3C7-4512-88DC-93DB5F5127A5Q27022883-C11ED323-6569-4043-9F71-6BE7924353E2Q27022957-8AADD02A-0BB1-43BA-8630-6E00D958E753Q27024456-DAA9E863-13C3-4911-896D-007714C1CF27Q27025300-B6212C1E-5662-4BA9-9C08-082E5D8113E0Q27026329-764B9884-78D9-4BC2-9FBA-76072FEFB0A1Q27026627-4AC7BA90-0FB0-40B6-A857-1B69045BDBD8Q27026665-517DF585-C6DF-459F-9C84-16214A746993Q27314843-1A5AE5E9-870E-484C-B8EF-89C64B12EC00
P2860
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Durable complete responses in ...... T-cell transfer immunotherapy
@ast
Durable complete responses in ...... T-cell transfer immunotherapy
@en
Durable complete responses in ...... T-cell transfer immunotherapy
@nl
type
label
Durable complete responses in ...... T-cell transfer immunotherapy
@ast
Durable complete responses in ...... T-cell transfer immunotherapy
@en
Durable complete responses in ...... T-cell transfer immunotherapy
@nl
prefLabel
Durable complete responses in ...... T-cell transfer immunotherapy
@ast
Durable complete responses in ...... T-cell transfer immunotherapy
@en
Durable complete responses in ...... T-cell transfer immunotherapy
@nl
P2093
P2860
P3181
P1476
Durable complete responses in ...... T-cell transfer immunotherapy
@en
P2093
Carolyn M Laurencot
Deborah E Citrin
Donald E White
Giao Q Phan
James C Yang
John R Wunderlich
Kathleen E Morton
Mark E Dudley
Marybeth S Hughes
Paul F Robbins
P2860
P304
P3181
P356
10.1158/1078-0432.CCR-11-0116
P407
P577
2011-04-15T00:00:00Z